[Long-term tolerance. Preventing lipoatrophy].
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004272:DNA, Mitochondrial / Q000187:drug effects; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects; D008134:Long-Term Care; D012307:Risk Factors; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects*; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects*; D000099227:Abacavir
D004272:DNA, Mitochondrial; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D018119:Stavudine; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir